Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Jeffersonville, Indiana Clinical Trials

A listing of Jeffersonville, Indiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (25) clinical trials

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This multicenter study will evaluate safety and efficacy of niraparib in combination with other anti-cancer agents. Combination 1 will combine niraparib with the anti-programmed cell death protein (PD)-1 monoclonal antibody cetrelimab, in participants with mCRPC. Combination 1 has 2 parts: in Part 1 (dose selection), participants will be enrolled to …

Phase

0.0 miles

Learn More »

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors Including Central Nervous System Tumors

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing …

Phase

3.7 miles

Learn More »

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

The primary objective of the Single-Dose Phase is to assess the pharmacokinetics (PK) and safety of single doses of NI-03 when administered at doses of 100 mg, 200 mg or 300 mg to subjects with chronic pancreatitis. The primary objective of the Double-Blind Phase of the study is to determine …

Phase

4.0 miles

Learn More »

A Study to Evaluate Safety Efficacy Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 (Cetrelimab) an Anti-PD-1 Monoclonal Antibody in Participants With Metastatic or Locally Advanced Urothelial Cancer With Selected FGFR Gene Alterations

This open-label (all people know identity of intervention) and multicenter (when more than one hospital or medical school team work on a medical research study) study of erdafitinib plus cetrelimab in participants with advanced urothelial cancer with selected fibroblast growth factor receptor (FGFR) gene alterations, will consists of 2 parts. …

Phase

4.0 miles

Learn More »

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part …

Phase

4.0 miles

Learn More »

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

This study will evaluate the safety, toxicity and efficacy of talactoferrin in reducing the incidence of all nosocomial infections in prematurely-born infants.

Phase

4.0 miles

Learn More »

Venetoclax and Lintuzumab-Ac225 in AML Patients

The study is a multicenter, open label Phase I/II trial. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 …

Phase

4.0 miles

Learn More »

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

This is a Phase I/II study. Phase I will be evaluating the safety of the FDA-approved Vemurafenib (960 mg orally, daily) in combination with Metformin (500 mg orally, twice daily for 2 weeks, then 850 mg orally,twice daily) in patients with unresectable Stage IIIC and Stage IV melanoma. Phase II …

Phase

4.0 miles

Learn More »

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body. This study will also demostrate how safe the combined drugs are when used to treat …

Phase

4.0 miles

Learn More »

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Small cell lung cancer accounts for approximately 15% of all lung cancer diagnoses in the United States (US), with 60-80% response rates to platinum-based chemotherapy in extensive disease. Despite its sensitivity to chemotherapy, small cell lung cancer is characterized by its tendency to spread to other locations in the body …

Phase

4.0 miles

Learn More »